Assertio Lands New $23.50/Share Cash Acquisition Deal with Zydus
ASRT has more than doubled off its 52-week low of $8.61.
Summary
Assertio Holdings announced it will be acquired by Zydus Worldwide DMCC for $23.50 per share in an all-cash transaction. This new definitive agreement significantly increases the acquisition price compared to the previously amended merger agreement with Garda Therapeutics, which was for $21.00 per share. The timeline shows Assertio has been actively engaged in M&A discussions, with recent news detailing extensions and amendments to the Garda offer. This new, higher offer from Zydus provides a substantial premium to shareholders and resolves the ongoing M&A uncertainty, despite recent weaker Q1 earnings. Traders will now focus on the deal's closing process and any regulatory approvals.
At the time of this announcement, ASRT was trading at $22.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $145.7M. The 52-week trading range was $8.61 to $22.59. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: Dow Jones Newswires.